The need for coordinated action against falsified and substandard medicines

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 3, 2013, Pages 286-

  Seear, Michael ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG LABELING; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; DRUG STORAGE; EDITORIAL; INTERNATIONAL COOPERATION; MEDICATION THERAPY MANAGEMENT; PATENT; PRIORITY JOURNAL; PUBLIC HEALTH; TOTAL QUALITY MANAGEMENT;

ANTITUBERCULAR AGENTS; COUNTERFEIT DRUGS; CRIME; HUMANS; ISONIAZID; RIFAMPIN;

EID: 84874098599     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0988     Document Type: Editorial

References (6)

1. Bate R, Jensen P, Hess K, Mooney L, Milligan J. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis 2013; 17: 308-311.
2. World Health Organization. Counterfeit medicines. WHO fact sheet no. 275. Geneva, Switzerland: WHO, 2012. http://www.who.int/medicentre/factsheets/fs275/ en/ Accessed December 2012.
3. Attaran A, Barry D, Bashir S, et al. How to achieve international action on falsified and substandard medicines. Brit Med J 2012; 345: e6724.
4. Newton P, Green M, Fernandez F, et al. Counterfeit anti-infective drugs. Lancet Infect Dis 2006; 6: 602-613.
5. Chan M. Opening remarks at the first meeting of the Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products. Buenos Aires, Argentina, 19 November 2012. Geneva, Switzerland: WHO, 2012. http://www.who.int/dg/speeches/2012/medical-products-20121119/en/index. html Accessed December 2012.
6. Seear M, Gandhi D, Carr R, et al. The need for better data about counterfeit drugs in developing countries: a proposed standard research methodology tested in Chennai, India. J Clin Pharm Ther 2011; 4: 488-495.